CN Mobile Logo

Search form


All Content

In a potential step toward precision endocrine therapy, a new study found that certain single nucleotide polymorphisms within CSMD1 are associated with changes in estrogen levels in postmenopausal breast cancer patients.

Circulating tumor DNA (ctDNA) measured by liquid biopsy was able to identify actionable mutations and provide a real-time molecular assessment of metastatic breast cancer, according to a new study.

A 43-year-old woman presents with vaginal bleeding, and endocervical biopsy is performed. What is you diagnosis?

This interview examines a study that looked at the health-related quality of life of multiple myeloma patients in a real-world setting who underwent maintenance therapy after autologous stem cell transplant.

This interview examines treatment-related cardiotoxicity and the risk of second malignancy in patients with Hodgkin lymphoma.

This interview examines the role of functional imaging to direct therapy (escalation or de-escalation) for early and advanced Hodgkin lymphoma.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy significantly increased response rates among women with BRCA1 or BRCA2 mutations and locally recurrent or metastatic breast cancer, according to a randomized phase II trial.

In this video we discuss longer term results of the phase III SABRINA study, which tested the safety and efficacy of subcutaneous rituximab in patients with follicular lymphoma.

Treatment with buparlisib in combination with endocrine therapy significantly improved PFS compared with placebo in patients with HR-positive advanced breast cancer that had progressed after treatment with everolimus plus exemestane.

The addition of estrogen deprivation to neoadjuvant chemotherapy did not significantly affect pathologic complete response in women with HR-positive, HER2-positive breast cancer.


By clicking Accept, you agree to become a member of the UBM Medica Community.